Skip NavigationSkip to Content
Return Return to Search Results

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments

  1. Author:
    Nam, J. S.
    Terabe, M.
    Mamura, M.
    Kang, N. J.
    Chae, H.
    Stuelten, C.
    Kohn, E.
    Tang, B.
    Sabzevari, H.
    Anver, M. R.
    Lawrence, S.
    Danielpour, D.
    Lonning, S.
    Berzofsky, J. A.
    Wakefield, L. M.

  2. Author Address

    Nam, Jeong-Seok, Mamura, Mizuko] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Inchon, South Korea. [Terabe, Masaki, Berzofsky, Jay A.] NCI, Vaccine Branch, Bethesda, MD 20892 USA. [Nam, Jeong-Seok, Mamura, Mizuko, Kang, Nu-Jin, Chae, Helen, Stuelten, Christina, Kohn, Ethan, Tang, Binwu, Wakefield, Lalage M.] NCI, Lab Canc Biol & Genet, Bethesda, MD 20892 USA. [Sabzevari, Helen] NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA. [Anver, Miriam R.; Lawrence, Scott] Sci Applicat Int Corp Frederick Inc, Pathol Histotechnol Lab, Frederick, MD USA. [Danielpour, David] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA. [Lonning, Scott] Genzyme Corp, Framingham, MA 01701 USA.
    1. Year: 2008
  2. Journal: Cancer Research
    1. 68
    2. 10
    3. Pages: 3835-3843
  4. Type of Article: Article
  1. Abstract:

    Overexpression of transforming growth factor beta (TGF-beta) is frequently associated with metastasis and poor prognosis, and TGF-beta antagonism has been shown to prevent metastasis in preclinical models with surprisingly little toxicity. Here, we have used the transplantable 4T1 model of metastatic breast cancer to address underlying mechanisms. We showed that efficacy of the anti-TGF-beta antibody 1D11 in suppressing metastasis was dependent on a synergistic combination of effects on both the tumor parenchyma and microenvironment. The main outcome was a highly significant enhancement of the CD8+ T-cell-mediated antitumor immune response, but effects on the innate immune response and on angiogenesis also contributed to efficacy. Treatment with 1D11 increased infiltration of natural killer cells and T cells at the metastatic site, and enhanced expression of coactivators (NKG2D) and cytotoxic effectors (perforin and granzyme B) on CD8+ T cells. On the tumor cells, increased expression of an NKG2D ligand (Rael gamma) and of a death receptor (TNFRSF1A) contributed to enhanced immune cell-mediated recognition and lysis. The data suggest that elevated TGF-beta expression in the tumor microenvironment modulates a complex web of intercellular interactions that aggregately promote metastasis and progression. TGF-beta antibodies reverse this effect, and the absence of a major effect of TGF-beta antagonism on any one cell compartment may be critical for a good therapeutic window and the avoidance of autoimmune complications.

    See More

  1. Keywords:

External Sources

  1. PMID: 18483268

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel